Table 1.
Statistical analysis for all quantifications
| Figure | N | Statistical test | F values main effect/T value | p value main effect | p value (post hoc) |
|---|---|---|---|---|---|
| 1H, DG height | Control: 6 | One-way ANOVA | F(2,12) = 16.508 | p = 3.58 × 10−4 | 20 dpi versus Control: p = 2.54 × 10−4 20 dpi versus 90 dpi: p = 0.027 |
| 20 dpi: 7 | |||||
| 90 dpi: 5 | |||||
| 1H, GCL thickness | Control: 6 | One-way ANOVA | F(2,12) = 28.8 | p = 2.62 × 10−5 | 20 dpi versus Control: p = 3.84 × 10−5 20 dpi versus 90 dpi; p = 1.02 × 10−4 |
| 20 dpi: 7 | |||||
| 90 dpi: 5 | |||||
| 1H, MF thickness | Control: 6 | One-way ANOVA | F(2,11) = 44.908 | p = 5.11 × 10−6 | 20 dpi versus Control: p = 4.61 × 10−6 20 dpi versus 90 dpi: p = 1.92 × 10−4 |
| 20 dpi: 5 | |||||
| 90 dpi: 3 | |||||
| 1H, NeuN density | Control: 6 | One-way ANOVA | F(2,12) = 20.67 | p = 0.0002 | 20 dpi versus Control: p = 0.004 20 dpi versus 90 dpi: p = 0.0026 |
| 20 dpi: 7 | |||||
| 90 dpi: 5 | |||||
| 2B | Control: 10 | t test | T(21) = 0.4254 | p = 0.6747 | |
| 20 dpi: 13 | |||||
| 2F, active NSCs density | Control: 5 | t test | T(9) = 5.800 | p = 0.0007 | |
| 20 dpi: 6 | |||||
| 2F, active NSCs fraction | Control: 5 | t test | T(9) = 5.542 | p = 0.0015 | |
| 20 dpi: 6 | |||||
| 2F, total neuroblast density | Control: 5 | t test | T(9) = 4.516 | p = 0.0027 | |
| 20 dpi: 6 | |||||
| 2F, early neuroblasts density | Control: 5 | t test | T(10) = 4.883 | p = 0.0028 | |
| 20 dpi: 7 | |||||
| 2F, early neuroblasts fraction | Control: 5 | t test | T(10) = 1.140 | p = 0.837 | |
| 20 dpi: 7 | |||||
| 2H, newborn neuron density | Control: 5 | t test | T(9) = 4.977 | p = 0.0025 | |
| 90 dpi: 6 | |||||
| 2H, neuron fraction/total CldU | Control: 5 | t test | T(9) = 3.208 | p = 0.0125 | |
| 90 dpi: 6 | |||||
| 3C | 1 month: | Two-way ANOVA | Treatment: F(1,158) = 169.19 | Treatment: p = 9.26 × 10−27 | Control versus VEGF: |
| Control: 11 | Time: p = 1.82 × 10−15 | 1 month: p = 5.82 × 10−4 | |||
| VEGF: 15 | Time: F(5,158) = 20.067 | 2 months: p = 5.11 × 10−4 | |||
| 2 months: | Interaction: p = 1.339 × 10−4 | 3 months: p = 0.008 | |||
| Control: 11 | Time × treatment interaction (control/VEGF) × time: F(5,158) = 5.384 | 4 months: p = 9.48 × 10−9 | |||
| VEGF: 15 | 5 months: p = 1.74 × 10−6 | ||||
| 3 months: | 7 months: p = 3.17 × 10−7 | ||||
| Control: 14 | |||||
| VEGF: 13 | |||||
| 4 months: | |||||
| Control: 13 | |||||
| VEGF: 15 | |||||
| 5 months: | |||||
| Control: 15 | |||||
| VEGF: 18 | |||||
| 7m: | |||||
| Control: 11 | |||||
| VEGF: 11 | |||||
| 3D | Control: 60 | One-way ANOVA | F(6,225) = 88.892 | p = 1.39 × 10−6 | Control versus 2 months: p = 4.2 × 10−06 |
| 1 month: 61 | Control versus 3 months: p = 1.45 × 10−22 | ||||
| 2 months: 15 | |||||
| 3 months: 46 | Control versus 4 months: p = 1.53 × 10−19 | ||||
| 4 months: 16 | Control versus 5 months: p = 8.32 × 10−18 | ||||
| 5 months: 18 | |||||
| 7 months: 11 | Control versus 7 months: p = 5.75 × 10−34 | ||||
| 4B | Control: 13 | t test | CA1: T(21) = −10.752 | CA1: p = 9.21 × 10−10 | |
| VEGF: 10 | DG: T(21) = −8.237 | DG: p = 7.39 × 10−8 | |||
| 4C | Control: 12 | t test | CA1 neuron density: T(20) = −0.047 | CA1 neuron density: p = 0.7 | |
| VEGF: 10 | CA1 height: T(20) = −3.63 | CA1 height: p = 0.002 | |||
| 5C | No transgene: 4 | One-way ANOVA | GCL thickness: F(2,12) = 0.6605 | GCL thickness: p = 0.5378 | |
| tTa only: 4 | DG height: F(2,12) = 1.906 | DG height: p = 0.199 | |||
| tTa-tetGFP: 5 | |||||
| 6D, NeuN density | Control: 8 | One-way ANOVA | F(2,21) = 61.526 | p = 1.655 × 10−9 | Control versus VEGF On: p = 6.279 × 10−9 |
| VEGF on: 8 | Control versus VEGF On>off: p = 2.11 × 10−6 | ||||
| VEGF on>off: 8 | VEGF On versus VEGF On>off: p = 0.002 | ||||
| 6D, GCL thickness | Control: 18 | One-way ANOVA | F(2,40) = 23.589 | p = 1.7 × 10−7 | Control versus VEGF On: p = 6.279 × 10−9 |
| VEGF on: 9 | Control versus VEGF On>off: p = 2.11 × 10−6 | ||||
| VEGF on>off: 16 | VEGF on versus VEGF On>off: p = 0.002 | ||||
| 6D, DG height | Control: 18 | One-way ANOVA | F(2,40) = 30.116 | p = 1.04 × 10−8 | Control versus VEGF on: p = 1.15 × 10−8 |
| VEGF on: 9 | Control versus VEGF on>off: p = 0.01 | ||||
| VEGF on>off: 16 | VEGF on versus VEGF on>off: p = 4.76 × 10−4 | ||||
| 6D, MF thickness | Control: 9 | One-way ANOVA | F(2,19) = 28.35 | p = 1.9 × 10−6 | Control versus On: p = 1.18 × 10−6 |
| VEGF on: 9 | Control versus on>off: p = 0.014 | ||||
| VEGF on>off: 7 | On versus On>off: p = 0.01 | ||||
| 6E | Same as 3D | Two-way ANOVA | Treatment: F(2,161) = 207.169 | Treatment: p = 2.99 × 10−45 | Control versus 3 months on >1 month off: 4.83 × 10−13 |
| On>off 1 month: 12 | Control versus 3 months on >3 months off: p = 1.65 × 10−4 | ||||
| On>off 2 months: 16 | Time: F(2,161) = 11.382 | Time: p = 2.37 × 10−5 | 5 months on versus 3 months on >2 months off: p = 4.83 × 10−13 | ||
| On>off 3 months: 30 | 7 months on versus 3 months on >3 months off: p = 4.82 × 10−13 | ||||
| Interaction: F(2,161) = 27.373 | Interaction: p = 5.84 × 10−11 | ||||
| 7D, total NSC density | Control: 11 | One-way ANOVA | F(2,28) = 27.632 | p = 0.22 | Control versus VEGF On: p = 0.019 |
| VEGF on: 7 | |||||
| VEGF on>off: 13 | |||||
| 7D, active NSC density | Control: 11 | One-way ANOVA | F(2,28) = 13.39 | p = 0.0002 | Control versus VEGF On: p = 0.0002 Control versus VEGF On>off: p = 0.0002 |
| VEGF on: 7 | |||||
| VEGF on>off: 13 | |||||
| 7D, fraction of active NSC | Control: 11 | One-way ANOVA | F(2,28) = 4.379 | p = 2.26 × 10−7 | Control versus VEGF On: p = 4.24 × 10−7 |
| VEGF on: 7 | Control versus VEGF On Off: p = 2.03 × 10−5 | ||||
| VEGF on>off: 13 | |||||
| 8B | Control: 15 | One-way ANOVA | F(2,31) = 50.405 | p = 1.8 × 10−10 | Control versus VEGF On>off p = 5.47 × 10−9 |
| VEGF on: 7 | VEGF on versus VEGF On>off: p = 9.53 × 10−8 | ||||
| VEGF on>off: 12 | |||||
| 8C, MVD | Control: 19 | One-way ANOVA | F(2,34) = 154.153 | p = 1.84 × 10−9 | Control versus VEGF On: p = 3.33 × 10−7 |
| VEGF on: 8 | Control versus VEGF on>off: p = 3.47 × 10−8 | ||||
| VEGF on>off: 10 | |||||
| 8C, total neuroblast density | Control: 19 | One-way ANOVA | F(2,32) = 58.735 | p = 1.9 × 10−11 | Control versus VEGF On: p = 5.208 × 10−9 Control versus VEGF on>off: p = 2.12 × 10−8 |
| VEGF on: 7 | |||||
| VEGF on>off: 10 | |||||
| 8D, late neuroblast density | Control: 14 | One-way ANOVA | F(2,28) = 26.836 | p = 3.09 × 10−7 | Control versus VEGF on p = 1.59 × 10−6 |
| VEGF on: 6 | Control versus VEGF on>off p = 1.69 × 10−5 | ||||
| VEGF on>off: 11 | |||||
| 8D, late neuroblast % | Control: 14 | One-way ANOVA | F(2,28) = 6.084 | p = 0.006 | Control versus VEGF on>off p = 0.01 |
| VEGF on: 6 | VEGF on versus VEGF on>off p = 0.031 | ||||
| VEGF on>off: 11 | |||||
| 9D | Control: 8 | One-way ANOVA | F(2,21) = 6.808 | p = 0.005 | Control versus VEGF On: p = 0.004 |
| VEGF on: 7 | VEGF On>off versus VEGF on: p = 0.028 | ||||
| VEGF on>off: 9 | |||||
| 9F | Control: 15 | Two-way ANOVA | Treatment: F(1,64) = 10.785 | Treatment: p = 0.002 | Control versus VEGF on: p = 0.004 |
| VEGF: 9 | Time: F(2,64) = 10.987 | Time: p = 7.9 × 10−5 | |||
| Time × treatment interaction: F(2,64) = 4.198 | Interaction: p = 0.019 | ||||
| 10B | Control: 18 | One-way ANOVA | F(2,45) = 47.84 | p = 7.27 × 10−12 | Control versus VEGF On: p = 8.08 × 10−9 |
| VEGF on: 15 | Control versus VEGF On>off: p = 5.15 × 10−9 | ||||
| VEGF on>off: 15 | |||||
| 10C, 12 months | Control: 7 | One-way ANOVA | F(2,29) = 34.5 | p = 1.55 × 10−5 | Control versus VEGF On: p = 1.02 × 10−5; control versus VEGF On>off: 0.005 |
| VEGF on: 4 | VEGF On versus VEGF On>off: p = 0.003 | ||||
| VEGF on>off: 10 | |||||
| 10C, 18 months | Control: 10 | One-way ANOVA | F(2,21) = 11.07 | p = 0.001 | Control versus VEGF On: p = 3.93 × 10−4 Control versus VEGF On>off: p = 0.048 |
| VEGF on: 5 | |||||
| VEGF on>off: 9 | |||||
| 10C | 12 months versus 18 months | Two-way ANOVA | Treatment: F(2,39) = 53.71 | Treatment: p = 1.5 × 10−9 | VEGF On 12 months versus VEGF on 18 months: p = 4.4 × 10−5 |
| Age: F(1,39) = 31.749 | Age: p = 1.66 × 10−6 | VEGF On>off 12 months versus VEGF on>off 18 months: p = 0.015 | |||
| Interaction: F(2,39) = 9.031 | interaction: p = 0.001 | ||||
| 10D | 12 months: | Two-way ANOVA | Treatment: F(1,25) = 25.164 | Treatment: p = 3.57 × 10−5 | 12 months Control versus On>off: p = 2.31 × 10−4 12 months On>off versus 18 months On>off: p = 3.83 × 10−4 |
| Control: 6 | Age: F(1,25) = 15.171 | Age: p = 0.001 | |||
| VEGF on>off: 5 | |||||
| 18 months: | Interaction: F(1,25) = 7.44 | Interaction: p = 0.011 | |||
| Control: 7 | |||||
| VEGF on>off: 11 | |||||
| 10E, 12 months | Control: 6 | One-way ANOVA | F(2,18) = 8.338 | p = 0.003 | Control versus VEGF On: p = 0.04 |
| VEGF on: 4 | VEGF On versus VEGF On-off: p = 0.04 | ||||
| VEGF on>off: 11 | |||||
| 10E, 18 months | Control: 9 | One-way ANOVA | F(2,17) = 20.527 | p = 2.9 × 10−5 | Control versus VEGF On: p = 1.37 × 10−5 Control versus VEGF On-off: p = 1.85 × 10−4 |
| VEGF on: 5 | |||||
| VEGF on>off: 6 | |||||
| 10E | 12 months versus 18 months | Two-way ANOVA | Treatment: F(2,53) = 34.516 | Treatment: p = 2.25 × 10−10 | On>off 12 months versus On>off 18 months: p = 0.0148 |
| Age: F(1,53) = 3.672 | Age: p = 0.032 | ||||
| Interaction: F(2,53) = 3.166 | interaction: p = 0.021 | ||||
| 10F, 12 months | Control: 8 | One-way ANOVA | F(2,21) = 7.61 | p = 0.003 | Control versus VEGF On: p = 0.002 |
| VEGF on: 5 | |||||
| VEGF on>off: 11 | |||||
| 10F, 18 months | Control: 11 | One-way ANOVA | F(2,29) = 46.408 | p = 9.16 × 10−10 | Control versus VEGF On: p = 6.43 × 10−9 Control versus VEGF On>off: p = 3.06 × 10−7 |
| VEGF on: 12 | |||||
| VEGF on>off: 9 | |||||
| 10F | 12 months versus 18 months | Two-way ANOVA | Treatment: F(2,50) = 36.843 | Treatment: p = 1.466 × 10−10 | On>off 12 months versus On>off 18: p = 0.025 |
| Age: F(1,50) = 4.529 | Age: p = 0.038 | ||||
| Interaction: F(2,50) = 3.192 | interaction: p = 0.05 | ||||
| 10G, 12 months | Control: 8 | One-way ANOVA | F(2,21) = 8.175 | p = 0.002 | Control versus VEGF On: p = 0.003 |
| VEGF on: 5 | VEGF On versus VEGF On>off: p = 0.007 | ||||
| VEGF on>off: 11 | |||||
| 10G, 18 months | Control: 11 | One-way ANOVA | F(2,29) = 34.5 | p = 2.14 × 10−8 | Control versus VEGF On: p = 2.36 × 10−8 Control versus VEGF On>off: p = 1.62 × 10−5 |
| VEGF on: 12 | |||||
| VEGF on>off: 9 | |||||
| 10G | 12 months versus 18 months | Two-way ANOVA | Treatment: F(2,50) = 30.784 | Treatment: p = 1.93 × 10−9 | On>off 12 months versus On>off 18 months: p = 0.0035 |
| Age F(1,50) = 7.067 | Age: p = 0.011 | ||||
| Interaction: F(2,50) = 4.568 | interaction: p = 0.015 |